CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1 enrolled
Drug / intervention
HALO90 Ablation catheterdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01103492
NCT01103492N/ACompleted

Treatment of Hemorrhagic Radiation Proctitis Using the Halo System

University Hospitals Cleveland Medical Center·interventional·Posted Apr 14, 2010·Updated Jan 5, 2015

In Brief

A clinical study evaluating HALO90 Ablation catheter for Pelvic Neoplasms. Completed, enrolled 1 participant across 1 site.

Detailed Summary

This study involves evaluating a procedure in which the study device, the HALO90 Ablation catheter, is used to heat a thin layer of tissue lining the rectum using radiofrequency (RF) energy in subjects suffering from radiation proctitis (acute inflammation of the inner lining of the rectum caused by the side effects of radiation treatments that can lead to bleeding). In medical procedures, the RF energy used with this device, has been historically used in shrinking or removing soft-tissue, for surgical cutting, and for stopping bleeding. The device is cleared by the Food and Drug Administration (FDA) for use in coagulation (to assit with stoping bleeding and clotting of blood) of tissue within the digestive tract. The device has been used in areas outside the esophagus (inner lining of the throat), including the rectum to treat radiation proctitis. The stoppage of bleeding of radiation proctitis, using the HALO device, may be one method to control the bleeding. The purpose of this study is to evaluate the effectiveness and record the results of treatment of radiation proctitis using the HALO device.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 14, 2010
Enrollment StartJul 1, 2008
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.2 years ago

Interventions

HALO90 Ablation catheterdevice

FDA approved endoscopic device for use in coagulation of tissue in the digestive tract using radiofrequency energy.